Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 7/20 | 0.48 |
| ▸ | HPSE | Q9Y251 | 6/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949000 | 0.92 | HPSE (0.53) | CHEK2HPSEHDAC6POLBMAPT | |
| SCHEMBL11949006 | 0.91 | SMN1; SMN2 (0.51) | CHEK2HPSEHDAC6POLBMAPT | |
| SCHEMBL11949039 | 0.90 | NR4A2 (0.55) | CHEK2HDAC6NR4A2 | |
| SCHEMBL11949038 | 0.90 | HDAC6 (0.55) | CHEK2HPSEHDAC6POLBMAPT | |
| SCHEMBL11949041 | 0.89 | PRSS12 (0.56) | CHEK2HDAC6MAPTSMN1; SMN2NR4A2 | |
| SCHEMBL11949029 | 0.89 | PRSS12 (0.56) | CHEK2HDAC6MAPTSMN1; SMN2NR4A2 | |
| SCHEMBL11949045 | 0.86 | BRPF1 (0.55) | AMY1ACYP2C19CHEK2POLBMAPT | |
| SCHEMBL11949059 | 0.86 | HDAC6 (0.51) | HPSEHDAC6POLBMAPTSMN1; SMN2 | |
| SCHEMBL11949009 | 0.86 | MMP2 (0.52) | CHEK2HPSEHDAC6NR4A2 | |
| SCHEMBL11949042 | 0.85 | HDAC6 (0.53) | CHEK2HPSEHDAC6NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232410-B2 | Benzimidazoles and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232410-B2 | Benzimidazoles and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2010-10-07 | — | — | US | disclosed |
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TBCD, TBC1D5, CFTR | AMY1A 2992/4885CYP1A2 1741/4885CYP3A4 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.